Skip to main content

Research News

  • Novavax COVID-19 Vaccine 90% efficacy in Phase 3 Trial

    Novavax, Inc announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. The study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.

  • New Study Investigates the Impact of ORi-Guided Oxygen Titration on Hyperoxemia-Mediated Morbidity During One-Lung Ventilation

    Masimo announced the findings of a study published in the Turkish Journal of Medical Sciences in which Dr. Ayten Saracoglu and colleagues at the Marmara University Pendik Training and Research Hospital in Istanbul evaluated the ability of ORi to guide oxygenation by measuring its impact on hyperoxemia-mediated morbidity during one-lung ventilation conducted as part of thoracic surgery. They concluded that ORi-guided oxygen titration may reduce hospital stay and increase patient safety.

  • Senolytics reduce COVID-19 symptoms in preclinical studies

    Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates the damaging impact of senescent cells in the body. In preclinical studies, the senolytic drugs discovered at Mayo significantly reduced inflammation, illness, and mortality from COVID infection in older mice. The findings appear in the journal Science.

  • Cholesterol metabolite induces production of cancer-promoting vesicles

    Scientists working to understand the cellular processes linking high cholesterol to breast cancer recurrence and metastasis report that a byproduct of cholesterol metabolism causes some cells to send out cancer-promoting signals to other cells. These signals are packaged in membrane-bound compartments called extracellular vesicles.

    Reported in the journal Endocrinology, the discovery could lead to the development of new anti-cancer therapies, researchers say.

  • One step closer to stem cell therapy for type 1 diabetes : Researcher

    Type 1 diabetes, which arises when the pancreas doesn’t create enough insulin to control levels of glucose in the blood, is a disease that currently has no cure and is difficult for most patients to manage. Scientists at the Salk Institute are developing a promising approach for treating it: using stem cells to create insulin-producing cells (called beta cells) that could replace nonfunctional pancreatic cells.

  • Protein identified as new therapeutic anti-viral target for COVID-19

    New research identified a novel interaction between the SARS-CoV-2 spike protein and the galectin-3-binding protein (LGALS3BP) which could be a new therapeutic anti-viral target. The research also found the presence of detectable viral RNA in blood in COVID-19 patients is a strong predictor of mortality.

  • Oral formulation for black fungus disease is developed by IIT, Hyderabad

    It is 2019 when Prof. Saptarshi Majumdar & Dr. Chandra Shekhar Sharma from the Department of Chemical Engineering has made a proven study about oral nanofibrous AMB to be effective for Kala Azar. This is a first-ever attempt to fabricate nanofibrous oral tablets of Amphotericin B for the potential cure of Leishmaniasis or Kala Azar. With the 2 years of advancement of examination, the researchers are now confident that the technology can be transferred to suitable pharma partners for large-scale production.

  • Cold chain management device developed by India for transport of COVID19 vaccine

    Indian Institute of Technology, Ropar in Punjab has developed a first-of-its-kind IoT device AmbiTag that records real-time ambient temperature during the transportation of perishable products, vaccines and even body organs and blood. That recorded temperature further helps to know whether that particular item transported from anywhere in the world is still usable or perished because of temperature variation. This information is particularly critical for vaccines including Covid-19 vaccine, organs and blood transportation.

  • Path breaking research in Huntingtons disease rapamycin target protein

    Researchers world-wide are focused on clearing the toxic mutant Huntingtin protein that leads to neuronal cell death and systemic dysfunction in Huntingtons disease (HD), a devastating, incurable, progressive neurodegenerative genetic disorder. Scientists in the Buck Institutes Ellerby lab have found that the targeting the protein called FK506-binding protein 51 or FKBP51 promotes the clearing of those toxic proteins via autophagy, a natural process whereby cells recycle damaged proteins and mitochondria and use them for nutrition.

  • New therapy for crimean congo hemorrhagic fever developed by researchers

    Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected. Their results are published online today in the journal Cell.

Subscribe to Research News